“We are very pleased to be invited by WFH to present our FVIII solution for home and in-office measurement of FVIII levels. Our approach provides a high-level of accuracy for FVIII measurements, particularly for long-acting and gene therapy-based FVIII therapies where conventional testing via activated partial thromboplastin time is less appropriate,” said Eugene Y. Chan,...Read more
Recent Posts by DMI
Blood analyzers to be qualified for spaceflight by NASA’s Commercial-Off-The Shelf (COTS) certification process CAMBRIDGE, Mass., September 30, 2019 – rHEALTH LLC, and its affiliate DNA Medicine Institute, Inc., today announced that rHEALTH ONE blood analyzers have been delivered to NASA and its prime contractor Zin Technologies for spaceflight qualification. The technology will undergo a rigorous...Read more
rHEALTH tests to be presented at the industry’s leading annual conference for laboratory medicine CAMBRIDGE, Mass., July 11, 2019 – rHEALTH LLC, and its affiliate DNA Medicine Institute, Inc., today announced that both of its abstracts have been accepted via peer-review from for the 2019 American Association of Clinical Chemistry (AACC) meeting. The titles and details...Read more
The rHEALTH ONE technology will be presented at CYTO 2019 in Vancouver, Canada on June 23 in a talk titled, "Personal 1.5 kg Microvolume Photon Counting Cytometer for Cell and Biomarker Analysis." Dr. Chan will be presenting the technology in the Parallel 03: New Technologies Session. The rHEALTH ONE is utilized for small volume analysis...Read more
rHEALTH Nanostrips, Vitals Device, and Fluidics Module to Receive U.S. Patent Protection. Expands patent protection for diagnose yourself, anywhere technology CAMBRIDGE, Mass., May 21, 2019 -- DNA Medicine Institute, Inc., and its affiliate rHEALTH LLC, today announced that three separate aspects of its technology platform has received a Notice of Allowance and two Issue Notifications from the...Read more
Recent Comments by DMI
No comments by DMI yet.